

## **ABSTRACT**

The present invention also relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of adrenomedullin as a biomarker for Raf kinase inhibitors.